403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Oncobayes Progressing OB-001 To Tackle ADC Resistance And TKI Brain Penetration
|
OncoBayes
/ Key word(s): Miscellaneous
OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration 07.10.2026 / 08:05 CET/CEST The issuer is solely responsible for the content of this announcement. LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetration of tyrosine kinase inhibitors (TKIs). OB-001 is a highly selective and effective inhibitor of two key efflux pumps (P-gp and BCRP), which are present both on the blood-brain barrier and on tumour cells. The product is being developed as a once-daily oral tablet, which will be used in combination with a number of gold standard oncology treatments in order to optimise their efficacy. In perfused-brain mouse studies, OB-001 pretreatment significantly raised brain exposure of four gold standard kinase inhibitors – whilst systemic (plasma) exposure remained broadly unchanged. Data presented at AACR 2026 demonstrated that OB-001 could increase the brain exposure of osimertinib by almost 400% with minimal systemic changes[1],[2]. Based on a translational PK-PD-TGI model for osimertinib, this increase is projected to deliver a step-change in CNS progression-free survival for EGFRm NSCLC patients. The improved control of brain metastases is still a major area of unmet need in NSCLC and breast cancer. The same efflux pumps have also been identified as a key resistance mechanism impacting ADCs – with the over-expression of these pumps leading to reduced payload concentrations in the tumour. Preclinical work using a bidirectional transporter assay demonstrated that OB-001 reduces efflux for several leading payloads, including SN-38 (e.g. sacituzumab govitecan, Trodelvy®), DM4 (e.g. mirvetuximab soravtansine, Elahere®) and DXd (e.g. trastuzumab deruxtecan, Enhertu®). Plans are currently underway to move into a parallel clinical trial programme to generate POC data in combination with osimertinib, and also evaluate T-DXd re-sensitisation. "This is a critical milestone for our team, and we are now well positioned to initiate our clinical plans with OB-001" said Jim Millen, Chief Executive Officer for OncoBayes. "OB-001 is on track to become a first-in-class drug with broad potential as a simple, oral adjunct to a range of blockbuster oncology therapies. This is truly a pipeline in a product opportunity." References: 1.AACR2026 Abstract 5873. 1 April 2026; 86 (7_Supplement): 5873. . 2.Cancer Research Communications 1 May 2026; 6 (5): 1213–1219. .  View original content: The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
2411504 07.10.2026 CET/CEST
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment